|Bid||74.95 x 800|
|Ask||76.98 x 1400|
|Day's range||76.50 - 77.42|
|52-week range||55.80 - 85.07|
|PE ratio (TTM)||9.99|
|Earnings date||23 Jul 2018 - 27 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||87.76|
Biotech companies and pharmacy benefit managers defied the overall market trend, despite more noise about President Trump's drug plan.
ValueAct now holds 16.2 million Citigroup shares. In other major first-quarter moves, ValueAct exited its positions in Microsoft (MSFT) and pharmacy benefit manager Express Scripts (ESRX). Perhaps the writing was on the wall about Microsoft.
Healthcare investors who were on the edges of their seats on Friday afternoon were relieved. Share prices of potentially-affected “middlemen” such as pharmacy-benefit managers, and to a lesser extent health insurers, fell sharply but then rebounded within minutes in late trading. After all, Mr. Trump’s comments were characteristically vague and didn’t unveil any immediate action to cut drug spending that might harm the profitability of companies like Express Scripts Holding or CVS Health.
WASHINGTON—President Donald Trump unveiled dozens of initiatives aimed at curbing high drug prices Friday, a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks. “We’re going to take on one of the biggest obstacles to affordable medicine: the tangled web of special interests,” Mr. Trump said from the White House Rose Garden.
Trump's plan to lower drug prices in the U.S. is "fair to all players" in the health-care industry, GOP Sen. Bill Cassidy argues.
President Donald Trump this afternoon unveiled his plan to crack down on high-priced drugs. Pharmaceutical industry investors were unfazed. In fact, the stocks of the firms he hit hardest—the "middlemen" known as pharmacy-benefit managers—jumped as traders saw little in the administration's program that could hurt PBM outfits like Express Scripts Holding (ESRX) and CVS Health (CVS), the parent of the benefit business Caremark.
Health care stocks whipsawed on Friday as President Donald Trump unveiled his long-awaited plan to lower prescription drug prices, dubbed "American Patients First."
ST. LOUIS , May 10, 2018 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) released new data today showing significantly improved clinical outcomes and lower drug spending for patients with complex, high-cost ...
Mallinckrodt's stock closed down more than 1 percent on Friday, in anticipation of the report being aired. But shares of the drug maker have since bounced back, closing up more than 6 percent Monday.
It's been a campaign promise going back to 2015, from both sides of the political aisle, but nothing substantial has changed.
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.
FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ -- Inside RxSM, a pharmacy savings program from Express Scripts (ESRX), today announced that it is making an additional 22 brand-name medications more affordable for people who currently have to pay the full list price for prescriptions. With the addition of these new products, Inside Rx now provides affordable access to more than 120 brand-name medications, adding discounted drugs for eight new therapy classes and expanding the program's current list of medications in five therapy classes for conditions that are prevalent in the U.S.
The St. Louis-based company said it had profit of $1.10 per share. Earnings, adjusted for non-recurring costs, came to $1.77 per share. The results surpassed Wall Street expectations. The average estimate ...
Express Scripts Holding Co. shares slipped in the extended session Wednesday after the pharmacy-benefits manager's quarterly revenue and outlook fell below Wall Street estimates. Express Scripts shares declined 1.3% after hours, following a 2.4% decline to close at $74.05 in the regular session. For the year, Express Scripts estimates earnings of $9 to $9.14 a share, down from a previously estimated range of $9.27 to $9.47 a share, because it suspended its share buyback program owing to its pending merger with Cigna Corp. Analysts had forecast earnings of $9.30 a share.
ST. LOUIS , May 2, 2018 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) announced consolidated 2018 first quarter net income of $623.2 million or $1.10 per diluted share. Consolidated 2018 ...
ST. LOUIS , May 2, 2018 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX), through its commitment to diversity and inclusion, has earned recognition among the Top 50 inclusive companies in the nation by DiversityInc, ...
Regeneron slipped to a four-year low Tuesday — prodding rival Amgen to also dip — after announcing a deal to cut the net price of its cholesterol drug.
Praluent's new price will be $4,500 to $8,000 per year, the range recommended in March by the Institute for Clinical and Economic Review.
STILLWATER, N.Y., April 30, 2018 /PRNewswire/ -- Saratoga County today announced an agreement with Inside Rx to offer the Inside RxSM discount savings card to Saratoga County residents as part of the County's Prescription Drug Discount Program. This program has been developed by the Saratoga County Board of Supervisors to help lower the prescription drug cost for County residents. "We are excited to be able to provide our residents with the opportunity to lower their prescription drug costs through this program," said Stillwater Supervisor Ed Kinowski, Chairman of the Board of Supervisors.
ST. LOUIS, April 25, 2018 /PRNewswire/ -- Many Americans on medications for chronic diseases are not concerned about missing doses, resent their spouses/partners reminding them to take their medicine and think they do a better job than others at taking their medication as prescribed. The survey found that nearly one-third of those taking prescription medications for chronic conditions say they are not concerned about forgetting to take their medications despite the fact that almost one-half believe it is the most important thing they can do to protect their health. They also don't want to be nagged by their spouse/partner about taking their medicine, rating them as the most annoying source of reminders to take their medicine. Although not concerned if they miss a dose or two, people still give themselves high marks for taking their medication as prescribed, with 54 percent of respondents claiming they do a better job of it than others — this is especially true for people 55 and older (60 percent).